3/27
08:00 am
otlk
Outlook Therapeutics, Inc. (NASDAQ: OTLK) was upgraded by analysts at BTIG Research from a "neutral" rating to a "buy" rating. They now have a $50.00 price target on the stock.
Low
Report
Outlook Therapeutics, Inc. (NASDAQ: OTLK) was upgraded by analysts at BTIG Research from a "neutral" rating to a "buy" rating. They now have a $50.00 price target on the stock.
3/27
07:16 am
otlk
Rating for OTLK
Low
Report
Rating for OTLK
2/15
07:26 am
otlk
Rating for OTLK
High
Report
Rating for OTLK
2/15
07:19 am
otlk
Outlook Therapeutics, Inc. (NASDAQ: OTLK) was upgraded by analysts at Chardan Capital from a "neutral" rating to a "buy" rating. They now have a $3.00 price target on the stock.
High
Report
Outlook Therapeutics, Inc. (NASDAQ: OTLK) was upgraded by analysts at Chardan Capital from a "neutral" rating to a "buy" rating. They now have a $3.00 price target on the stock.
1/25
09:05 am
otlk
Rating for OTLK
Low
Report
Rating for OTLK
1/25
09:05 am
otlk
Rating for OTLK
Low
Report
Rating for OTLK
1/25
07:30 am
otlk
Outlook Therapeutics, Inc. (NASDAQ: OTLK) was upgraded by analysts at Guggenheim from a "neutral" rating to a "buy" rating.
Low
Report
Outlook Therapeutics, Inc. (NASDAQ: OTLK) was upgraded by analysts at Guggenheim from a "neutral" rating to a "buy" rating.
1/25
07:30 am
otlk
Outlook Therapeutics, Inc. (NASDAQ: OTLK) was upgraded by analysts at Guggenheim from a "neutral" rating to a "buy" rating.
Low
Report
Outlook Therapeutics, Inc. (NASDAQ: OTLK) was upgraded by analysts at Guggenheim from a "neutral" rating to a "buy" rating.